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We evaluated the pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse trans-
criptase inhibitors (NNRTIs) in Ugandan adults. The study design was a three-period crossover study (3
tablets [600 mg of lopinavir/150 mg of ritonavir {600/150 mg}], 4 capsules [533/133 mg], and 2 tablets [400/100
mg] twice a day [BD]; n  40) of lopinavir-ritonavir with NNRTIs and a parallel one-period study (2 tablets
BD; n 20) without NNRTIs. Six-point pharmacokinetic sampling (0, 2, 4, 6, 8, and 12 h) was undertaken after
observed intake with a standardized breakfast. Ugandan DART trial participants receiving efavirenz (n  20),
nevirapine (n 18), and no NNRTI (n 20) had median ages of 41, 35, and 37 years, respectively, and median
weights of 60, 64, and 63 kg, respectively. For the no-NNRTI group, the geometric mean (percent coefficient of
variation [%CV]) lopinavir area under the concentration-time curve from 0 to 12 h (AUC0-12) was 110.1 (34%)
g  h/liter. For efavirenz, the geometric mean lopinavir AUC0-12 (%CV) values were 91.8 g  h/liter (58%),
65.7 g  h/liter (39%), and 54.0 g  h/liter (65%) with 3 tablets, 4 capsules, and 2 tablets BD, respectively,
with corresponding (within-individual) geometric mean ratios (GMR) for 3 and 2 tablets versus 4 capsules of
1.40 (90% confidence interval [CI], 1.18 to 1.65; P  0.002) and 0.82 (90% CI, 0.68 to 0.99; P  0.09),
respectively, and the apparent oral clearance (CL/F) values were reduced by 58% and 1%, respectively. For
nevirapine, the geometric mean lopinavir AUC0-12 (%CV) values were 112.9 g  h/liter (30%), 68.1 g  h/liter
(53%), and 61.5 g  h/liter (52%), respectively, with corresponding GMR values of 1.66 (90% CI, 1.46 to 1.88;
P < 0.001) and 0.90 (90% CI, 0.77 to 1.06; P  0.27), respectively, and the CL/F was reduced by 57% and 7%,
respectively. Higher values for the lopinavir concentration at 12 h (C12) were observed with 3 tablets and
efavirenz-nevirapine (P  0.04 and P  0.0005, respectively), and marginally lower C12 values were observed
with 2 tablets and efavirenz-nevirapine (P  0.08 and P  0.26, respectively). These data suggest that 2 tablets
of lopinavir-ritonavir BD may be inadequate when dosed with NNRTIs in Ugandan adults, and the dosage
should be increased by the addition of an additional adult tablet or a half-dose tablet (100/25 mg), where
available.
When efavirenz (a CYP450 inducer) and lopinavir-ritonavir
(metabolized by CYP450) are coadministered, a decrease in
lopinavir plasma concentrations has been observed (8). In the-
ory, this could lead to subtherapeutic lopinavir concentrations,
the development of virological failure, and, potentially, the
emergence of resistance mutations, particularly in the absence
of viral load monitoring. Therefore, an increase from the stan-
dard dose of 3 capsules (400 mg of lopinavir/100 mg of ritona-
vir [400/100 mg]) to 4 capsules (533/133 mg) twice daily was
recommended during the coadministration of lopinavir-ritona-
vir capsules (Kaletra) with nonnucleoside reverse transcriptase
inhibitors (NNRTIs) in HIV-infected patients.
A solid formulation of lopinavir-ritonavir tablets (Aluvia
tablets; based on Meltrex technology) is now approved for the
treatment of HIV infection. Each tablet contains 200 mg/50 mg
lopinavir-ritonavir, so the standard dose is 2 tablets (rather
than 3 capsules) twice daily (BD). The tablets are preferred to
the capsules because of heat stability, a lack of a food effect,
and lower pill burden.
However, there are few data on the pharmacokinetic (PK)
interactions between NNRTIs and lopinavir-ritonavir tablets,
particularly in African populations, and the previously recom-
mended 533/133-mg twice-daily capsule dose cannot be
achieved with 200/50-mg tablets. In the United States, original
recommendations for lopinavir-ritonavir tablets with NNRTIs
were 400/100 mg twice daily, but a dose of 600/150 mg twice
daily was to be considered if decreased lopinavir susceptibility
was suspected. In Europe, a dose of 600/150 mg twice daily
with close monitoring was recommended. These recommenda-
tions were based on two healthy-volunteer studies that found
that the administration of lopinavir-ritonavir tablets at 400/100
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mg twice daily with efavirenz led to decreases in the lopinavir
area under the concentration-time curve (AUC) by 20% and a
decrease in the trough concentration (Ctrough) by 27% but
suggested that the increased lopinavir bioavailability with the
tablet may compensate for this effect (9). In contrast, admin-
istration of lopinavir-ritonavir tablets at 600/150 mg twice daily
with efavirenz led to 36% increases in lopinavir AUC and
Ctrough values (11) compared to a dose of 400/100 mg twice
daily without efavirenz. A half-dose (100/25-mg) lopinavir-
ritonavir tablet is now licensed, and late in 2008, both U.S. and
European recommendations changed to a dose of 500/125 mg
(two 200/50-mg tablets plus one 100/25-mg half-dose tablet)
twice daily based on a third healthy volunteer study, which
found exposures with this dosing scheme and efavirenz similar
to those for 400/100 mg twice daily without efavirenz (15).
Lopinavir-ritonavir is the main protease inhibitor used for
second-line therapy in resource-limited settings, where the vast
majority of patients receive antiretroviral therapy (ART) un-
der the public health approach to ART (7) without routine
viral load monitoring and where half-dose lopinavir-ritonavir
tablets may not always be available. Concerns about low
plasma lopinavir concentrations with 2 tablets twice daily and
NNRTIs are therefore particularly important in these settings.
However, increasing the dose to 3 tablets twice a day may also
lead to long-term toxicity, and there is contradictory evidence
on whether low trough levels are associated with virological
failure (1, 2). Therefore, early in 2008 (before the change in
dosing recommendations), we performed a three-period cross-
over study of Ugandan patients receiving lopinavir-ritonavir
with NNRTIs and a parallel one-period pharmacokinetic study
of those receiving lopinavir-ritonavir without NNRTIs within
the Development of Anti-Retroviral Therapy in Africa
(DART) trial.
MATERIALS AND METHODS
The DART trial was a randomized controlled trial evaluating ART manage-
ment strategies for 3,316 symptomatic, previously untreated HIV-infected adults
with CD4 cell counts of 200 cells/mm3 in Uganda and Zimbabwe (3). The main
comparison was clinically driven monitoring (CDM) versus laboratory and clin-
ical monitoring (LCM). All participants initiated triple-drug ART with cofor-
mulated zidovudine-lamivudine (Combivir) plus tenofovir, nevirapine, or aba-
cavir. All participants switching to second-line therapy following clinical or
immunological failure (in the LCM group only) received lopinavir-ritonavir
(Kaletra capsules or Aluvia tablets) supported by an NNRTI, if this was not in
the failing regimen, and further nucleoside reverse transcriptase inhibitors
(NRTI). The DART trial received ethics approval in Uganda, Zimbabwe, and
the United Kingdom, and all participants gave informed consent.
After the introduction of lopinavir-ritonavir tablets in Uganda and Zimbabwe,
additional ethics approval was obtained for a pharmacokinetic (PK) study with
two parts in Ugandan DART centers, including the Joint Clinical Research
Centre, Kampala, Uganda; its satellite at the Infectious Diseases Institute, Mu-
lago Hospital; and the MRC/UVRI Uganda Research Unit on AIDS (second
part only). The first part was a three-period crossover study recruiting 20 par-
ticipants receiving efavirenz and 20 participants receiving nevirapine with lopi-
navir-ritonavir as a second-line therapy (following three first-line NRTIs). As all
participants on NNRTIs and lopinavir-ritonavir at these clinics were already
receiving 3 tablets of lopinavir-ritonavir twice a day when the PK study started,
the order was not randomized. A full six-point PK curve was generated at
enrollment, when participants were receiving 3 lopinavir-ritonavir tablets BD
plus NNRTI (with or without an additional NRTI[s]), and then after 2 weeks of
4 lopinavir-ritonavir capsules BD and 2 weeks of 2 lopinavir-ritonavir tablets BD.
Venous blood (5 ml) was sampled 0, 2, 4, 6, 8, and 12 h after observed intake with
a standardized meal of two fried samosas (moderate-fat meal) and tea after the
blood drawing at time zero. The sampling schedule was based on a pragmatic
design previously utilized for studying lopinavir-NNRTI interactions in patients
from the United Kingdom (5). The second part was a single PK study recruiting
20 participants from the same Ugandan DART centers who received 2 lopinavir-
ritonavir tablets BD without NNRTIs (also as a second-line therapy following
first-line treatment with 2 NRTIs and an NNRTI) and who underwent a single
full six-point PK curve as described above. Participants for this second part of the
study were also recruited from the DART center in Entebbe, Uganda. To more
closely reflect real-life conditions, participants were prescribed lopinavir-ritona-
vir tablets and lopinavir-ritonavir capsules, which they stored at home and
brought to the clinic on each day of PK testing. However, each participant was
visited at home to confirm that capsules were stored at the appropriate temper-
ature, using either a refrigerator or clay pots. All participants were checked for
the absence of gastrointestinal disease before each day of PK testing, and none
were taking rifampin concurrently. Plasma was stored at 20°C before shipment
to Liverpool, United Kingdom, for analysis. Details of age, gender, and body
weight were obtained from the DART database. HIV-1 RNA was not routinely
assessed within the DART trial. All participants provided additional informed
consent for participation in the PK substudy.
Lopinavir (and ritonavir) concentrations were determined by a validated high-
performance liquid chromatography (HPLC)–tandem mass spectrometry
method as described previously (4). Briefly, an internal standard (20 l [500
ng/ml]) (catalog no. Ro31-9564; Roche Discovery, Welwyn, United Kingdom)
and acetonitrile (400 l; VWR Laboratory Supplies, Poole, United Kingdom)
were added to aliquots (100 l) of calibrators, quality controls (QCs), and patient
plasma. After mixing, centrifugation, and the addition of ammonium formate
buffer (100 l [20 mM]; Fisher Scientific, Loughborough, United Kingdom),
samples were analyzed by HPLC-tandem mass spectrometry (Waters Quattro
Premier XE; Waters Corporation, MA) via an Acuity UPLC bridged ethyl hybrid
C18 column (Waters Corporation, MA). The interassay variation was between
6.9% and 8.4% for low, medium, and high QCs. Intra-assay variabilities were
5.7%, 4.7%, and 2.3%, with accuracies of 100%, 99.9%, and 98.5% for low,
medium, and high QCs, respectively. The limits of quantitation of the plasma
lopinavir and ritonavir assays are 103 and 26 ng/ml, respectively. The Liverpool
laboratory participates in an external quality assurance program (KKGT, Neth-
erlands).
Noncompartmental analysis. Standard analyses were done by using Stata 10
software. For each day of PK monitoring and each drug (lopinavir and ritonavir),
the area under the concentration-time curve over 0 to 12 h (AUC0-12) using the
trapezoidal rule with scheduled time points, maximum concentration of drug in
plasma (Cmax), time to maximum concentration of drug in plasma (Tmax), and
lopinavir concentration at 12 h (C12) (trough) were calculated. Values under the
lower limit of quantitation (LLQ) (103 and 26 ng/ml for lopinavir and ritonavir,
respectively) were imputed as LLQ-1 in the AUC0-12 calculation. Separate anal-
yses were conducted for patients taking nevirapine, efavirenz, and no NNRTIs.
Geometric mean ratios (GMRs) and their 90% confidence intervals for lopinavir
and ritonavir AUC0-12, Cmax, and C12 comparing data for 2 lopinavir-ritonavir
tablets BD and 3 lopinavir-ritonavir tablets BD with 4 lopinavir-ritonavir cap-
sules BD were generated by using a paired t test on log transformations and then
back-transforming values to the normal scale. Unpaired t tests were used to
compare NNRTI and no-NNRTI groups. The impact of age, gender, hemoglobin,
and body weight was assessed in linear-mixed regression models for AUC0-12, Cmax,
and C12, including patient-level random effects.
Population PK modeling of lopinavir and ritonavir. Nonlinear mixed-effects
modeling was performed by using NONMEM (version VI 2.0, level 1.1, double
precision; ICON Development Solutions, Ellicott City, MD) with first-order
conditional estimation with interaction (FOCE-I). Model fit was assessed by
statistical and graphical methods. As the “no-NNRTI” control group contained
different patients from each of the NNRTI groups, we developed separate
models for lopinavir and ritonavir in the presence of nevirapine and efavirenz
and made a primary comparison between 2 and 3 tablets versus 4 capsules BD,
which was the standard of care prior to the change of the formulation. The main
pharmacokinetic parameter of interest was the apparent oral clearance (CL/F).
Samples lower than the LLQ (LLQ) of the drug assays were included in the
analysis as LLQ/2 (51.5 ng/ml and 13 ng/ml for lopinavir and ritonavir, respec-
tively). A one-compartment model with first-order absorption best described
both lopinavir and ritonavir data, parameterized by apparent oral clearance
(CL/F), volume of distribution (V/F), and absorption rate constant (ka). Interoc-
casion variability on CL/F significantly improved the fit; interindividual variabil-
ity on CL/F was removed, as it was negligible (106). For lopinavir models, the
ka was fixed to 1.22 h1 (10). No parameters were fixed for the model for
ritonavir plus efavirenz, whereas V/F was fixed to 42.1 liters (the value obtained
for the ritonavir-efavirenz model) due to estimation issues for the ritonavir-plus-
nevirapine model. Interoccasion variability was described by an exponential
model, and residual error was described by a proportional model for lopinavir
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and a combined proportional-additive model for ritonavir. The ritonavir
AUC0-12 was significantly associated with the lopinavir CL/F, and the lopinavir
AUC0-12 was significantly associated with the ritonavir CL/F; these associations
were described by power relationships. The inclusion of a factor for 3 or 2 tablets
versus 4 capsules BD significantly improved the fit.
For each model, the association between CL/F and other model parame-
ters was described by the following equations: CL/Fij  1  (RTVij/cons)2 
3
I(3 tablets BD)  4
I(2 tablets BD)  exp(ij) (cons  3.16 for efavirenz and 2.84 for
nevirapine [median ritonavir AUC0-12 in each group]) for lopinavir and CL/Fij 
1  (LPVij/cons)2  3I(3 tablets BD)  4I(2 tablets BD)  exp(ij) (cons  71.92 for
efavirenz and 79.78 for nevirapine [median lopinavir AUC0-12 in each group]) for
ritonavir, where CL/Fij is the CL/F of the ith individual on the jth occasion, 1 is
the population parameter estimate, 2 is the factor associated with the ritonavir
(RTV) AUC0-12 on the lopinavir (LPV) CL/F and the lopinavir AUC0-12 on the
ritonavir CL/F, RTVij and LPVij are the AUC0-12 of ritonavir and lopinavir,
respectively, for the ith individual on the jth occasion (constants normalize these
AUC0-12 values [as described above]), 3 is the relative change in CL/F for 3
tablets versus 4 capsules BD, 4 is the relative change in CL/F for 2 tablets versus
4 capsules BD, and ij is the interoccasion variability (mean of zero; variance,
2). Residual error was described as follows: Y  F 	 (1 
 ε1) for lopinavir and
Y  F 	 (1 
 ε1) 
 ε2 for ritonavir, where Y is the observed concentration, F is
the predicted concentration, and ε1 and ε2 are the proportional and additive
random effects, which are assumed to have a mean of zero and variances of 12
and 22, respectively.
Ninety-five percent prediction intervals (P2.5 to P97.5) were constructed from
1,000 simulated patients using the fixed and random effects of the final models.
A total of 93% and 94% of the observed concentrations were within the predic-
tion intervals for the efavirenz and nevirapine models, respectively.
RESULTS
In total, 60 participants taking lopinavir-ritonavir with efa-
virenz (n  21), nevirapine (n  19), or no NNRTIs (n  20)
were recruited. However, two participants (one taking efa-
virenz and one taking nevirapine) had very low lopinavir (4/6
PK samples LLQ) and ritonavir (6/6 PK samples LLQ)
measurements on the day of PK evaluation with 4 lopinavir-
ritonavir capsules BD and were therefore excluded from fur-
ther analyses because the group receiving 4 lopinavir-ritonavir
capsules BD was the reference group for comparing bioequiva-
lence and also due to suspected noncompliance despite re-
ported observed intake. However, both excluded participants
had not reported missed pills according to nurse pill counts
and the self-reported adherence questionnaire and had phar-
macokinetic parameters with 2 and 3 tablets BD that were
within (but toward the lower end of) the ranges observed for
other participants. Only 3 (0.4%) of the remaining 682 lopina-
vir plasma measurements were LLQ (103 ng/ml), with two
being 12-h values for tablets for one patient and the other
being an initial value (t  0) for 2 tablets BD. A total of 8/682
(1.2%) plasma ritonavir measurements were LLQ (26 ng/ml)
(6 at 12 h and 2 at 0 h). Enrollment characteristics are shown
in Table 1. A total of 6/20 participants (30%) taking efavirenz,
versus 13/19 participants (72%) taking nevirapine and 14/20
participants (70%) with no NNRTI, were women, reflecting
issues with the use of efavirenz in women who may become
pregnant.
Mean plasma concentrations of lopinavir and ritonavir are
shown over time for those receiving concurrent efavirenz, ne-
virapine, or no NNRTIs in Fig. 1. There was little difference
between the two NNRTIs efavirenz and nevirapine in sum-
mary PK parameters for lopinavir (Table 2) and ritonavir (Ta-
ble 3), and we found no independent effect of sex, age, weight,
hemoglobin level, body mass index (BMI), or body surface
area (BSA) on pharmacokinetic parameters. For AUC0-12,
Cmax, and C12, standard deviations were similar across tablet
TABLE 1. Patient characteristics at enrollment
Parameter
Value for group
Efavirenz Nevirapine No NNRTIs
No. of patients in enrolled in PK substudy 21 19 20
No. of patients included in analysis (%)a 20 (100) 18 (100) 20 (100)
No. of patients at center (%)
Joint Clinical Research Centre, Uganda 17 (85) 10 (56) 15 (75)
Academic Alliance, Uganda 3 (15) 8 (44)
Entebbe, Uganda 5 (25)
No. of male patients (%) 14 (70) 5 (28) 6 (30)
No. of female patients (%) 6 (30) 13 (72) 14 (70)
Median age (yr) (range) 41 (32–52) 35 (27–63) 37 (28–68)
Median wt (range) 59.8 (49–75) 63.6 (52–85) 63.3 (48–111)
Median BMI (kg/m2) (range) 23.2 (17.1–26.7) 24.8 (20.0–33.2) 24.3 (19.2–37.1)
Median hemoglobin level (g/dl) (range) 13.9 (11.2–16.5) 13.6 (8.7–16.8) 13.5 (7.9–15.7)
No. of patients taking other NRTIs (%)
None 1 (5)
Lamivudine 1 (5)
Abacavir 4 (20) 2 (11)
Didanosine 14 (70) 14 (78)
Tenofovir 1 (6)
Lamivudine 
 tenofovir 1 (6)
Lamivudine 
 zidovudine 2 (10)
Lamivudine 
 abacavir 8 (40)
Zidovudine 
 abacavir 1 (5)
Didanosine 
 abacavir 9 (45)
a Excluding two patients with low levels of lopinavir and ritonavir receiving 4 capsules of lopinavir-ritonavir BD.
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and capsule formulations, being somewhat higher only for par-
ticipants taking efavirenz with 3 lopinavir-ritonavir tablets BD.
In particular, there was no suggestion of higher standard de-
viations with 4 capsules of lopinavir-ritonavir BD compared to
the tablet formulations (12).
The mean lopinavir AUC0-12 was substantially lower than
the expected 83 g  h/ml (Kaletra capsules summary of prod-
uct characteristics, August 2008 [also see reference 16]) for
both the group taking 4 lopinavir-ritonavir capsules BD (geo-
metric means of 65.7 g  h/ml with efavirenz and 68.1
g  h/ml with nevirapine) and the group taking 2 tablets of
lopinavir-ritonavir BD (geometric means, 54.0 g  h/ml with
efavirenz and 61.5 g  h/ml with nevirapine). In contrast, the
geometric mean lopinavir AUC0-12 values were 110.1 g  h/ml
for those receiving 2 tablets of lopinavir-ritonavir BD without
NNRTIs and 91.8 g  h/ml and 112.9 g  h/ml for those re-
ceiving 3 tablets BD with efavirenz or nevirapine, respectively,
which is more similar to the 113.2 g  h/ml expected for lopi-
navir-ritonavir tablets (Aluvia summary of product character-
istics, December 2009). Similarly, the mean ritonavir AUC0-12
was substantially lower for both the group taking 4 capsules of
lopinavir-ritonavir BD (geometric means, 2.86 g  h/ml with
efavirenz and 2.60 g  h/ml with nevirapine) and the group
taking 2 lopinavir-ritonavir tablets BD (geometric means, 2.43
g  h/ml with efavirenz and 2.43 g  h/ml with nevirapine),
whereas the geometric mean ritonavir AUC0-12 values were
3.69 g  h/ml for those receiving 2 tablets of lopinavir-ritona-
vir BD without NNRTIs and 4.14 g  h/ml and 4.89 g  h/ml
for those receiving 3 tablets BD with efavirenz or nevirapine,
respectively. Estimated half-lives (t1/2) of lopinavir differed
across groups similarly to the lopinavir AUC0-12; however,
ritonavir half-lives were more similar across groups.
We found that 15%, 15%, and 40% of those receiving efa-
virenz with 3 lopinavir-ritonavir tablets, 4 lopinavir-ritonavir
capsules, and 2 lopinavir-ritonavir tablets BD, respectively, had
C12 values of 1 g/ml, a minimum trough concentration
suggested previously by some groups to be an important
threshold (1, 13) but not supported by data from the manu-
facturer (2). Equivalent percentages for patients receiving ne-
virapine were 0%, 22%, and 28%, respectively, and none of
those receiving 2 tablets of lopinavir-ritonavir BD without
NNRTIs had a C12 of 1 g/ml. However, 40%, 5%, and 15%
of those receiving efavirenz and 56%, 28%, and 17% of those
receiving nevirapine had C12 values 5 g/ml, compared to
60% of those receiving 2 tablets of lopinavir-ritonavir BD
without NNRTIs.
Comparison of data for the lopinavir-ritonavir 2- and 3-tab-
let BD groups to data for the 4-capsule BD group as a refer-
ence (as this was the recommended dose for lopinavir-ritonavir
capsules with NNRTIs) showed that the AUC0-12, Cmax, and
C12 values were at least 30 to 40% higher for the group re-
ceiving 3 tablets of lopinavir-ritonavir BD and were generally
10 to 20% lower for the group receiving 2 tablets of lopinavir-
ritonavir BD (Table 4). Only the Cmax for the group receiving
2 lopinavir-ritonavir tablets BD with efavirenz was formally
bioequivalent to 4 lopinavir-ritonavir capsules BD. Compari-
son of data for the group receiving 3 lopinavir-ritonavir tablets
BD with NNRTI to data for the group receiving 2 lopinavir-
ritonavir tablets BD without NNRTIs showed that the levels
were generally similar those for the group receiving 3 tablets
FIG. 1. Mean plasma concentrations (95% CI) of lopinavir and ritonavir over time.
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BD, although only the lopinavir AUC0-12 with nevirapine met
formal criteria for bioequivalence (90% confidence interval
[CI] within the range of 0.8 to 1.25). In contrast, both the
AUC0-12 and C12 were statistically significantly reduced by over
50% for the group receiving 2 tablets BD and NNRTIs com-
pared to the group receiving 2 tablets BD without NNRTIs.
Population PK modeling of interactions between lopinavir-
ritonavir and nevirapine or efavirenz. Compared to 4 capsules
(533/133 mg) BD, the lopinavir CL/F for patients also receiving
efavirenz was reduced by 58% and 1% for 3 tablets (600/150
mg) and 2 tablets (400/100 mg) BD, respectively, and was
reduced by 57% and 7%, respectively, for those also receiving
nevirapine (Table 5). Compared to data for the group receiv-
ing 4 capsules BD, the ritonavir CL/F for patients also receiv-
ing efavirenz was reduced by 58% and 14% for the patients
receiving 3 and 2 tablets BD, respectively, and by 55% and
13% for those also receiving nevirapine, respectively (Table 5).
No other factors (age, gender, hemoglobin level, and body
weight) were associated with the lopinavir or ritonavir CL/F.
DISCUSSION
When coadministered with efavirenz or nevirapine in HIV-
infected Ugandan patients, the lopinavir AUC0-12 and C12 are
significantly higher and the CL/F is significantly lower with 3
tablets BD than for the previously recommended dose of 4
lopinavir-ritonavir capsules BD. The lopinavir AUC0-12 and
C12 are marginally lower with 2 tablets BD than with the
previously recommended dose of 4 lopinavir-ritonavir capsules
BD, although the CL/F values were similar. However, the
lopinavir AUC0-12 and C12 for patients taking 3 tablets BD plus
NNRTIs are similar to those for patients taking 2 tablets BD
without NNRTIs in whom lopinavir and ritonavir exposures
were similar to that observed for studies in resource-rich set-
tings (4). Low plasma C12 values for patients taking 2 tablets
BD plus NNRTIs may increase the risk of virological failure,
although these levels are similar to the Ctrough values seen for
patients taking 800/200 mg (4 tablets) four times a day (QD),
which has shown good efficacy in patients without lopinavir
resistance (6). Nevertheless, the fact that levels were lower
than both those for patients taking 4 capsules BD with
NNRTIs and those for patients taking 2 tablets BD without
NNRTIs supports the most recent licensing information that a
dose increment above 2 lopinavir-ritonavir tablets BD with
concurrent NNRTIs should be considered.
Our study was powered on within-patient comparisons of the
different doses and/or formulations with each NNRTI, efa-
virenz and nevirapine, and not the between-patient compari-
sons with the “no-NNRTI” group, which would have required
substantially more patients to allow for between-patient vari-
ability. Rather, the “no-NNRTI” control group was intended
to provide an independent estimate of the expected lopinavir
exposure in Ugandan patients receiving tablets compared with
historical Caucasian controls. We found similar AUC0-12 val-
ues for these patients receiving 2 tablets BD without NNRTIs
(geometric mean of 110.1 versus 113.2 g  h/ml in the most
recent summary of product characteristics), more similar to
values for those receiving 3 tablets of lopinavir-ritonavir BD
with NNRTIs.
While current labeling now recommends 500/125 mg (two
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200/50-mg tablets plus one 100/25-mg half-dose tablet) BD
with NNRTIs, this may be difficult for resource-limited set-
tings, particularly where half-dose lopinavir-ritonavir tablets
are not available. In this situation, our study has shown that
plasma PK levels for patients receiving 3 tablets BD with
NNRTIs are similar to those for patients taking 2 tablets BD
without NNRTIs, suggesting that this dosing scheme could be
used with levels of toxicity (diarrhea, lipid abnormalities, and
TABLE 4. GMR of plasma lopinavir and ritonavir pharmacokinetic measurements compared with data for 4 lopinavir-ritonavir capsules BD
and 2 lopinavir-ritonavir tablets BD without NNRTIsa
Dose and parameter Dose forcomparison
Value for group
Lopinavir plus: Ritonavir plus:
Efavirenz (n  20) Nevirapine (n  18) Efavirenz (n  20) Nevirapine (n  18)
GMR (90% CI) P GMR (90% CI) P GMR (90% CI) P GMR (90% CI) P
4 capsules BD
AUC0-12 (g/ml) 3 tablets BD 1.40 (1.18, 1.65) 0.002 1.66 (1.46, 1.88) 0.001 1.44 (1.19, 1.75) 0.003 1.88 (1.56, 2.26) 0.001
2 tablets BD 0.82 (0.68, 0.99) 0.09 0.90 (0.77, 1.06) 0.27 0.85 (0.69, 1.04) 0.18 0.93 (0.77, 1.13) 0.54
Cmax (g/ml) 3 tablets BD 1.34 (1.16, 1.54) 0.002 1.45 (1.28, 1.66) 0.0001 1.41 (1.14, 1.73) 0.01 1.81 (1.50, 2.19) 0.001
2 tablets BD 0.90 (0.78, 1.05) 0.26 0.92 (0.80, 1.06) 0.31 0.88 (0.72, 1.08) 0.30 0.91 (0.71, 1.15) 0.49
C12 (g/ml) 3 tablets BD 1.48 (1.09, 2.02) 0.04 2.31 (1.64, 3.24) 0.0005 1.33 (1.06, 1.67) 0.04 1.59 (1.18, 2.15) 0.01
2 tablets BD 0.62 (0.39, 0.98) 0.08 0.80 (0.57, 1.12) 0.26 0.80 (0.60, 1.06) 0.18 0.78 (0.61, 1.00) 0.10
t1/2 (h) 3 tablets BD 1.14 (0.92, 1.41) 0.31 1.05 (0.74, 1.49) 0.81 0.88 (0.73, 1.06) 0.24 0.71 (0.60, 0.83) 0.002
2 tablets BD 0.87 (0.67, 1.13) 0.36 0.63 (0.47, 0.84) 0.01 0.89 (0.74, 1.08) 0.32 0.71 (0.60, 0.85) 0.004
2 tablets BD with
no NNRTI
AUC0-12 (g/ml) 3 tablets BD 0.83 (0.66, 1.05) 0.21 1.03 (0.87, 1.21) 0.81 1.12 (0.86, 1.47) 0.48 1.33 (1.06, 1.66) 0.05
2 tablets BD 0.49 (0.38, 0.63) 0.001 0.56 (0.45, 0.70) 0.001 0.66 (0.51, 0.86) 0.01 0.66 (0.51, 0.85) 0.01
Cmax (g/ml) 3 tablets BD 0.91 (0.75, 1.11) 0.45 1.00 (0.87, 1.15) 0.98 1.15 (0.89, 1.47) 0.37 1.40 (1.11, 1.77) 0.02
2 tablets BD 0.62 (0.51, 0.74) 0.001 0.63 (0.53, 0.76) 0.001 0.72 (0.57, 0.92) 0.03 0.70 (0.54, 0.90) 0.03
C12 (g/ml) 3 tablets BD 0.51 (0.31, 0.83) 0.03 0.96 (0.72, 1.27) 0.80 0.87 (0.60, 1.25) 0.53 1.03 (0.78, 1.37) 0.85
2 tablets BD 0.21 (0.12, 0.37) 0.001 0.33 (0.22, 0.49) 0.001 0.52 (0.37, 0.73) 0.003 0.51 (0.37, 0.70) 0.001
t1/2 (h) 3 tablets BD 0.60 (0.43, 0.83) 0.01 0.93 (0.69, 1.26) 0.70 0.80 (0.68, 0.95) 0.04 0.80 (0.68, 0.93) 0.02
2 tablets BD 0.45 (0.33, 0.62) 0.001 0.52 (0.39, 0.69) 0.001 0.82 (0.70, 0.95) 0.04 0.81 (0.70, 0.93) 0.02
a Note that boldface type indicates parameters meeting the formal definition of bioequivalence (90% CI within the range of 0.8 to 1.25). Comparison to data for 4
capsules BD is a within-person comparison and is powered for bioequivalence. Comparison to data for 2 tablets BD without NNRTIs is a between-person comparison
and is not powered for equivalence.
TABLE 5. Population pharmacokinetic model parameter estimates and standard errors for lopinavir and ritonavir in the presence of
nevirapine or efavirenza
Drug and parameter
Value
Efavirenz Nevirapine
Estimate RSE(%)
IOV
(%)
RSE
(%) Estimate
RSE
(%)
IOV
(%)
RSE
(%)
Lopinavir
CL/F (liters/h) 6.81 6.0 17.4 47.4 6.54 4.1 11.0 43.9
V/F (liters) 104 13.0 138 11.5
ka (h
1) 1.22 1.22
Factor associated with RTV AUC0-12 on CL/F 0.633 13.2 0.612 11.0
Relative change in LPV CL/F for 600/150 mg 0.415 5.1 0.434 7.2
Relative change in LPV CL/F for 400/100 mg 0.986 6.8 0.929 5.3
Residual error, proportional (%) 39.5 14.3 33.3 15.9
Ritonavir
CL/F (liters/h) 37.7 7.2 14.2 51.0 36.6 5.5 15.1 43.5
V/F (liters) 42.1 30.9 42.1
ka (h
1) 0.111 13.7 0.0819 17.0
Factor associated with LPV AUC0-12 on CL/F 0.882 9.9 1.12 7.4
Relative change in RTV CL/F for 600/150 mg 0.421 7.6 0.452 5.9
Relative change in RTV CL/F for 400/100 mg 0.856 7.6 0.872 8.0
Residual error
Proportional (%) 29.5 40.0 41.5 20.2
Additive (mg/liter) 0.058 46.6 0.039 40.1
a CL/F, apparent oral clearance of lopinavir; V/F, apparent volume of distribution; ka, absorption rate constant; LPV, lopinavir; RTV, ritonavir; AUC0-12, area under
the concentration-time curve over the dosing interval; RSE, relative standard error; IOV, interoccasion variability RSE  (SEestimate/estimate) 	 100.
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cardiovascular risk) similar to that seen for the population
receiving lopinavir-ritonavir tablets without NNRTIs. Clearly,
however, such a regimen will increase costs by 50%. An alter-
native option not evaluated in this study would be split dosing
with 3 tablets in the morning and 2 tablets in the evening. As
there is diurnal variation, with evening troughs lower than
morning troughs upon even dosing, this would be the most
logical split-dosing regimen but may be difficult for patients to
follow and may be liable to dosing errors.
Our study has several limitations. Due to financial con-
straints, patients were not admitted the previous night, and
therefore, only the dose at time zero, and not the preceding
dose, was observed. However, concentrations at time zero were
generally slightly higher than the C12, which does not support
nonadherence as a driver of low trough levels. In healthy vol-
unteers, the C0 (morning) was also slightly higher than the C12
(evening). Plasma concentrations were not measured an hour
after intake, and therefore, our estimates of Tmax are only
approximate, particularly for those patients taking NNRTIs,
where this appeared to be somewhat closer to intake than in
the group taking lopinavir-ritonavir tablets without NNRTIs.
While the AUC0-12 may also be slightly underestimated, this
should not affect differences between groups because the sam-
pling schedule was the same for each day of PK evaluation. We
also found surprisingly low lopinavir and ritonavir exposures
with 4 capsules BD, particularly given the somewhat higher
levels than expected for those receiving 2 tablets BD without
NNRTIs. This finding may suggest problems with either the
stability of the capsule formulation or its bioavailability in
tropical settings. We also found lower levels of lopinavir with 3
tablets BD than those found by a previous study of efavirenz in
a resource-rich setting (11). In particular, it is unclear why
ritonavir levels were reduced so much by NNRTIs, with both
capsule and tablet lopinavir-ritonavir, since these have gener-
ally been considered less-strong enzyme inducers than other
concomitant medications such as rifampin. However, poten-
tially, this could be a combined effect of the NNRTI and
lopinavir, as lopinavir does induce ritonavir concentrations.
Compliance was measured during this substudy (and through-
out the DART trial) by using nurse pill counts and patient
self-reporting; a missing dose(s) in the last 4 days was an
exclusion criterion, and none of the included patients reported
missing lopinavir-ritonavir doses in the last month during the
substudy period. Finally, lipids were not routinely measured,
limiting the assessment of short-term toxicity at the different
doses used in this PK crossover study.
In general, the data from the population PK analysis are
consistent with data from the noncompartmental analysis. The
pharmacokinetic parameters have similarities with those re-
ported in the literature (10, 14); however, the CL/F was higher.
This is not unusual since here the population estimates of lopi-
navir and ritonavir CL/F values are those in the presence of
NNRTIs at a dose of 533/133 mg twice daily. The use of
different formulations, doses, and enzyme inducers, i.e., efa-
virenz versus nevirapine, together with a different control
group from those receiving NNRTIs precluded the use of a
single combined model for all data. Moreover, it was shown
previously that a model incorporating the inhibition of lopina-
vir CL/F by ritonavir concentrations at each sampling time
better describes lopinavir pharmacokinetics (14); however, the
available data did not allow this type of analysis. Thus, the
population PK models suggest that the differences in AUC0-12
values are mostly likely due to differences in CL/F and unlikely
to be due to differences in absorption, although this could not
be investigated directly due to a lack of data for the absorption
phase.
Overall, therefore, this study suggests that the revised rec-
ommendation of a regimen of 500/125 mg (two 200/50-mg
tablets plus one 100/25-mg half-dose tablet) lopinavir-ritonavir
BD with NNRTIs is appropriate. Where half-dose lopinavir-
ritonavir tablets are not available, the dose should be increased
by the adding an additional adult tablet in the morning; alter-
natively, a dose of 3 tablets BD with NNRTIs is likely to
provide exposure similar to that with 2 tablets BD without
NNRTIs but is considerably more expensive. This study high-
lights the importance of conducting pharmacokinetic evalua-
tions of target populations in resource-limited settings, where
comparable plasma pharmacokinetic characteristics, and, con-
sequently, the impact of an adverse drug-drug interaction, can-
not be assumed.
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